Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617

Clinical Nuclear Medicine

Volumn 41, Issue 7, 2016, Pages 572-573

  Schlenkhoff, Carl Diedrich ^a   Knüpfer, Eberhard ^b   Essler, Markus ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Private Office for Urology   (Germany)

Author keywords

177Lu PSMA therapy; 68Ga PSMA PET; Castrate resistant prostate cancer; Hormone therapy

Indexed keywords

GONADORELIN; LUTETIUM 177; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOLIGAND; DIPEPTIDE; LUTETIUM; PSMA-617; RADIOISOTOPE; SINGLE HETEROCYCLIC RINGS;

AGED; ARTICLE; CANCER HORMONE THERAPY; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HORMONE RESPONSE; HUMAN; MALE; METASTASIS; VERY ELDERLY; DIAGNOSTIC IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

AGED, 80 AND OVER; DIPEPTIDES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LUTETIUM; MALE; NEOPLASM METASTASIS; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; TREATMENT OUTCOME;

EID: 84959094706     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001200     Document Type: Article

References (8)

1. Afshar-Oromieh A, Hetzheim H, Kratochwil C, et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697-1705.
2. Kratochwil C, Giesel FL, Eder M, et al. [177Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:987-988.
3. Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56:1169-1176.
4. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of Lutetium-177- labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19: 5182-5191.
5. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMAligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
6. Afshar-Oromieh A, Haberkorn U, Eder M, et al. [68Ga]Gallium-labelled PSMAligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18 F-FECH. Eur J Nucl Med Mol Imaging. 2012;39:1085-1086.
7. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective comparison of 18 Ffluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-1190.
8. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.